Lead ATAC candidate HDP-101 shows strong clinical activity and safety in phase 8 cohort
Category: News
CGT Catapult annual review shows sector’s impact on economy and patient access
Early treatment with vamorolone shows sustained efficacy and improved safety profile
Deal strengthens CNS portfolio and ensures continuity of access for MS patients
Three-year trial results reveal long-term improvements in pain and lesion resolution
New self-loading reagents offer unmatched flexibility for immunologists
First-in-class mast cell selective c-Kit inhibitor enters clinical testing in Germany
SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA
Faster scans and same-day results improve patient experience across community sites
